PMPRB Summary of VCUs & Orders - 2009
Click on medicine to view details of VCU
| Date of Approval |
Medicine |
Patentee |
% Above Guidelines |
Price Reduction1 |
Excess Revenues2 |
Payments |
Patent Status |
| VCUs |
| Oct. 16, 2009 |
Andriol |
Schering-Plough Canada Inc. |
See VCU |
See VCU |
$3,392,652.63 |
$348,605.86 |
Expiration: Mar. 27, 2020 |
| Oct. 16, 2009 |
Neulasta1 |
Amgen Canada Inc. |
See VCU |
See VCU |
$6,730,120.32 |
$6,730,120.32 |
Expiration:Jul. 31, 2024 |
| Oct. 5, 2009 |
Brevibloc |
Baxter Corporation |
See VCU |
2009 MNE: $1.0086 |
$212,440.76 |
$212,440.76 |
Expiration: Jan. 2, 2022 |
| April 24, 2009 |
Concerta2 |
Janssen-Ortho Inc. |
See VCU |
See VCU |
$1,464,441.58 |
$1,464,441.58 |
Expiration: Nov. 1, 2017 |
| April 23, 2009 |
Eligard |
sanofi-aventis Canada Inc. |
See VCU |
See VCU |
$13,127,953.14 |
$13,127,953.14 |
Expiration: Sept. 1, 2021 |
| Mar. 4, 2009 |
Suprax |
sanofi-aventis Canada Inc. |
See VCU |
2009 MNE: $3.4304 |
$97,900.30 |
$97,900.30 |
Expiration: Nov. 1, 2011 |
| February 23, 2009 |
Vepesid |
Bristol-Myers Squibb Canada Co. |
See VCU |
Yes |
$53,161.48 |
$53,161.48 |
Expiration Oct 1, 2014 |
| February 19, 2009 |
Strattera3 |
Eli Lilly Canada Inc. |
See VCU |
Yes |
$15,326,066.49 |
$15,326,066.49 |
Expiration Sept 1, 2018 |
| ORDER |
| |
|
|
|
|
|
|
|
1 The Board issued an Order - PMPRB-09-D1-NEULASTA - on October 21, 2009, concluding the proceeding in the matter of Amgen Canada Inc. and the patented medicine Neulasta, initiated with the issuance of a Notice of Hearing on March 16, 2009.
2 The Board issued an Order – PMPRB-06-D1-CONCERTA - on April 24, 2009, concluding the proceeding in the matter of Janssen-Ortho Inc. and the patented medicine Concerta initiated with the issuance of a Notice of Hearing on July 24, 2006.
3 The Board issued an Order – PMPRB-06-D1-STRATTERA - on February 19, 2009, concluding the proceeding in the matter of Eli Lilly Canada Inc. and the patented medicine Strattera initiated with the issuance of a Notice of Hearing on December 15, 2006.